DAFNA Capital Management’s Neos Therapeutics, Inc NEOS Stock Holding History

DAFNA Capital Management’s Portfolio NEOS Stock Details NEOS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q1	–	Sell	-27,500	Closed	-$45K	–	86
2018 Q4	$45K	Hold	27,500	–	–	0.02%	83
2018 Q3	$133K	Hold	27,500	–	–	0.05%	74
2018 Q2	$172K	Hold	27,500	–	–	0.08%	74
2018 Q1	$228K	Hold	27,500	–	–	0.11%	66
2017 Q4	$281K	Hold	27,500	–	–	0.15%	65
2017 Q3	$252K	Sell	27,500 -182,373	-87%	-$1.39M	0.16%	62
2017 Q2	$1.53M	Buy	209,873 +114,600	+120%	+$865K	1.09%	33
2017 Q1	$686K	Buy	95,273 +56,400	+145%	+$350K	0.58%	49
2016 Q4	$227K	Hold	38,873	–	–	0.2%	59
2016 Q3	$256K	Hold	38,873	–	–	0.18%	66
2016 Q2	$361K	Hold	38,873	–	–	0.29%	65
2016 Q1	$419K	Sell	38,873 -24,527	-39%	-$259K	0.36%	68
2015 Q4	$908K	Hold	63,400	–	–	0.81%	37
2015 Q3	$1.33M	Buy	+63,400	New	+$1.4M	1.32%	24

Other funds holding NEOS

SCM

Stonepine Capital Management Bend, Oregon $177M AUM 91.13% 1-Year Est. Return

NCM

Nantahala Capital Management New Canaan, Connecticut $3.01B AUM 119.46% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

SFM

Sphera Funds Management Tel Aviv, Israel $767M AUM 119.71% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return

Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return

Broadfin Capital New York $747M AUM 100.56% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

DAFNA Capital Management's NEOS Position: Q1 2019 in Review

DAFNA Capital Management sold out of Neos Therapeutics, Inc (NEOS) in Q1 2019, closing a stake of 27,500 shares — an estimated $45K sold.

DAFNA Capital Management first reported a position in NEOS in Q3 2015 and held it in 14 quarters. The position peaked at $1.53M in Q2 2017. 63 funds tracked by Wall St. Rank hold NEOS as of Q1 2019.

DAFNA Capital Management reported no remaining Neos Therapeutics, Inc position as of Q1 2019 after selling out during the quarter.
DAFNA Capital Management sold 27,500 Neos Therapeutics, Inc shares in Q1 2019, an estimated $45K.
DAFNA Capital Management first reported a position in Neos Therapeutics, Inc in Q3 2015 and held it in 14 quarters.
DAFNA Capital Management's Neos Therapeutics, Inc position peaked at $1.53M in Q2 2017.
63 funds tracked by Wall St. Rank held Neos Therapeutics, Inc as of Q1 2019.

Based on DAFNA Capital Management's 13F filing for Q1 2019, filed 15 May 2019.